The Potential Use of HIV Vaccines for the Treatment of HIV Infection: Scientific Summary of the State-of-the-Art
viral burden have been observed in the data that have been thus far collected and analyzed. Currently, there are at least 3 ongoing Phase II placebo controlled clinical trials in HIV infected individuals of various products: MicroGeneSys gpl60 LAI strain (600 patients and 280 patients) and Immune Response Corp. (Salk Vaccine) whole virus, envelope depleted (103 patients). In addition, at least 3 Phase II trials are in development: 1 with Genentech gpl20 MN strain (100 patients) and 2 with ImmunoAG gpl60 MN strain (100 patients each). Data from these trials will be essential in order to clearly determine the effect of these vaccine candidates on surrogate markers such as CD4 counts and viral burden. 18
-
Scan 1
Page #1
-
Scan 2
Page #2
-
Scan 3
Page #3
-
Scan 4
Page 1
-
Scan 5
Page 2
-
Scan 6
Page 3
-
Scan 7
Page 4
-
Scan 8
Page 5
-
Scan 9
Page 6
-
Scan 10
Page 7
-
Scan 11
Page 8
-
Scan 12
Page 9
-
Scan 13
Page 10
-
Scan 14
Page 11
-
Scan 15
Page 12
-
Scan 16
Page 13
-
Scan 17
Page 14
-
Scan 18
Page 15
-
Scan 19
Page 16
-
Scan 20
Page 17
-
Scan 21
Page 18
-
Scan 22
Page #22
-
Scan 23
Page #23
-
Scan 24
Page #24
-
Scan 25
Page #25
-
Scan 26
Page #26
-
Scan 27
Page #27
-
Scan 28
Page #28
-
Scan 29
Page #29
-
Scan 30
Page #30
-
Scan 31
Page #31
-
Scan 32
Page #32
-
Scan 33
Page #33
-
Scan 34
Page #34
-
Scan 35
Page #35
-
Scan 36
Page #36
-
Scan 37
Page #37
-
Scan 38
Page #38
-
Scan 39
Page #39
-
Scan 40
Page #40
-
Scan 41
Page #41
-
Scan 42
Page #42
-
Scan 43
Page #43
-
Scan 44
Page #44
-
Scan 45
Page #45
-
Scan 46
Page #46
-
Scan 47
Page #47
-
Scan 48
Page #48
About this Item
- Title
- The Potential Use of HIV Vaccines for the Treatment of HIV Infection: Scientific Summary of the State-of-the-Art
- Author
- National Institutes of Health (U.S.)
- Canvas
- Page 18
- Publication
- 1992-11-23
- Subject terms
- reports
- Series/Folder Title
- Government Response and Policy > Law > gp160 trials and controversy > National Institute of Health (U.S.) GP160 Meeting, Blue-Ribbon Panel (1992)
- Item type:
- reports
Technical Details
- Collection
- Jon Cohen AIDS Research Collection
- Link to this Item
-
https://name.umdl.umich.edu/5571095.0463.013
- Link to this scan
-
https://quod.lib.umich.edu/c/cohenaids/5571095.0463.013/21
Rights and Permissions
The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.
Related Links
IIIF
- Manifest
-
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0463.013
Cite this Item
- Full citation
-
"The Potential Use of HIV Vaccines for the Treatment of HIV Infection: Scientific Summary of the State-of-the-Art." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0463.013. University of Michigan Library Digital Collections. Accessed June 22, 2025.